A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Bjarnason, Georg A
  • Basappa, Naveen S
  • Knox, Jennifer J
  • Kollmannsberger, Christian K
  • Reaume, M Neil Neil
  • Lalewski, Pawel
  • Macfarlane, Robyn Jane
  • MacKenzie, Mary J
  • Hotte, Sebastien
  • Heng, Daniel Vick Chin
  • Soulieres, Denis
  • Miller, Jessie

publication date

  • May 20, 2013